Get the Stockscreener App
1.96
0.51%
-0.01
After Hours:
2.04
0.08
+4.08%
Palisade Bio Inc stock is traded at $1.96, with a volume of 3.45M.
It is down -0.51% in the last 24 hours and up +16.67% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.97
Open:
$1.99
24h Volume:
3.45M
Relative Volume:
0.90
Market Cap:
$340.61M
Revenue:
$250.00K
Net Income/Loss:
$-24.15M
P/E Ratio:
-1.8393
EPS:
-1.0656
Net Cash Flow:
$-12.40M
1W Performance:
-6.67%
1M Performance:
+16.67%
6M Performance:
-1.51%
1Y Performance:
+151.28%
1-Day Range:
$1.87
$1.99
1-Week Range:
$1.87
$2.22
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.96 | 340.61M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Insider Buying: Robert Baltera Acquires 45,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock By Investing.com - Investing.com Australia
Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com UK
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Palisade Bio to present clinical updates at Lee... - Pluang
Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
Insider Buying: Robert Baltera Acquires 50,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com - Investing.com South Africa
Palisade Bio chief medical officer Jones sells $106,535 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock By Investing.com - Investing.com Canada
Palisade Bio CEO, CFO Finley sells $303k in stock - Investing.com
Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys - Stock Titan
[Form 4] PALISADE BIO, INC. Insider Trading Activity - Stock Titan
Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax - Stock Titan
Insider Spends US$59k Buying More Shares In Palisade Bio - simplywall.st
Form 144 PALISADE BIO For: 7 July By Investing.com - Investing.com Nigeria
[144] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock - Investing.com
Form 4 Palisade Bio Inc For: 6 July By Investing.com - Investing.com South Africa
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock By Investing.com - Investing.com South Africa
Palisade Bio (PALI) director adds 30,000 shares in open-market buys - Stock Titan
Price to book forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Stifel Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates Palisade Bio stock rating on FDA trial clearance - Investing.com South Africa
Enterprise value to revenue forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? - Stocktwits
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2500 Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Index - marketscreener.com
Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis - marketscreener.com
Palisade Bio stock surges on FDA clearance for UC trial By Investing.com - Investing.com South Africa
Palisade Bio stock surges on FDA clearance for UC trial - Investing.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Climbs As Palisade Bio Loads Up Dealmakers - StocksToTrade
PALI Stock Grinds Higher As Pipeline And Board Upgrades Draw Trader Focus - timothysykes.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Value Benchmark - marketscreener.com
Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial - Moomoo
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):